Discovery of 1H-pyrazolo[3,4-b]pyrazine derivatives as selective allosteric inhibitor of protein tyrosine phosphatase SHP2 for the treatment of KRAS^G12C-mutant non-small cell lung cancer

References

• Barford, D., & Neel, B. G. (1998). Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure (London, England: 1993), 6(3), 249–254. https://doi.org/10.1016/s0969-2126(98)00027-6
   PubMed Web of Science ®Google Scholar
• Butterworth, S., Overduin, M., & Barr, A. J. (2014). Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Medicinal Chemistry, 6(12), 1423–1437. https://doi.org/10.4155/fmc.14.88
   PubMed Web of Science ®Google Scholar
• Chan, R. J., & Feng, G. S. (2007). PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood, 109(3), 862–867. https://doi.org/10.1182/blood-2006-07-028829
   PubMed Web of Science ®Google Scholar
• Chen, Y.-N P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., Dobson, J. R., Deng, Z., Fei, F., Firestone, B., Fodor, M., Fridrich, C., Gao, H., Grunenfelder, D., Hao, H.-X., … Fortin, P. D. (2016). Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature, 535(7610), 148–152. https://doi.org/10.1038/nature18621
   PubMed Web of Science ®Google Scholar
• Chen, L., Pernazza, D., Scott, L. M., Lawrence, H. R., Ren, Y., Luo, Y., Wu, X., Sung, S.-S., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2010). Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochemical Pharmacology, 80(6), 801–810. https://doi.org/10.1016/j.bcp.2010.05.019
   PubMed Web of Science ®Google Scholar
• Chen, L., Sung, S.-S., Yip, M. L. R., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2006). Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology, 70(2), 562–570. https://doi.org/10.1124/mol.106.025536
   PubMed Web of Science ®Google Scholar
• Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., Grunenfelder, D., Ho, S., Kang, Z. B., Karki, R., Kato, M., Keen, N., LaBonte, L. R., Larrow, J., Lenoir, F., … LaMarche, M. J. (2016). Allosteric inhibition of SHP2: Identification of a potent, selective, and orally efficacious phosphatase inhibitor. Journal of Medicinal Chemistry, 59(17), 7773–7782. https://doi.org/10.1021/acs.jmedchem.6b00680
   PubMed Web of Science ®Google Scholar
• Grossmann, K. S., Rosário, M., Birchmeier, C., & Birchmeier, W. (2010). The tyrosine phosphatase Shp2 in development and cancer. Advances in Cancer Research, 106, 53–89. https://doi.org/10.1016/s0065-230x(10)06002-1
   PubMed Web of Science ®Google Scholar
• Hellmuth, K., Grosskopf, S., Lum, C. T., Würtele, M., Röder, N., von Kries, J. P., Rosario, M., Rademann, J., & Birchmeier, W. (2008). Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proceedings of the National Academy of Sciences of the United States of America, 105(20), 7275–7280. https://doi.org/10.1073/pnas.0710468105
   PubMed Web of Science ®Google Scholar
• Ho, C. S. L., Tüns, A. I., Schildhaus, H.-U., Wiesweg, M., Grüner, B. M., Hegedus, B., Schuler, M., Schramm, A., & Oeck, S. (2021). HER2 mediates clinical resistance to the KRAS(G12C) inhibitor sotorasib, which is overcome by co-targeting SHP2. European Journal of Cancer (Oxford, England: 1990), 159, 16–23. https://doi.org/10.1016/j.ejca.2021.10.003
   PubMed Web of Science ®Google Scholar
• Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998). Crystal structure of the tyrosine phosphatase SHP-2. Cell, 92(4), 441–450. https://doi.org/10.1016/s0092-8674(00)80938-1
   PubMed Web of Science ®Google Scholar
• LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., Dore, M., Dunstan, D., Fan, J., Fekkes, P., Firestone, B., Fodor, M., Garcia-Fortanet, J., Fortin, P. D., Fridrich, C., … Zhu, S. (2020). Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer. Journal of Medicinal Chemistry, 63(22), 13578–13594. https://doi.org/10.1021/acs.jmedchem.0c01170
   PubMed Web of Science ®Google Scholar
• Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., Kopecky, D. J., Liu, L., Lopez, P., Low, J. D., Ma, V., Minatti, A. E., Nguyen, T. T., Nishimura, N., Pickrell, A. J., … Cee, V. J. (2020). Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. Journal of Medicinal Chemistry, 63(1), 52–65. https://doi.org/10.1021/acs.jmedchem.9b01180
   PubMed Web of Science ®Google Scholar
• Li, J., Jie, H.-B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., Kane, L. P., & Ferris, R. L. (2015). PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Research, 75(3), 508–518. https://doi.org/10.1158/0008-5472.Can-14-1215
   PubMed Web of Science ®Google Scholar
• Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., Ojofeitimi, I., Hotaki, L. T., Spillman, D., Pazdur, R., Beaver, J. A., & Singh, H. (2022). FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 28(8), 1482–1486. https://doi.org/10.1158/1078-0432.Ccr-21-3074
   PubMed Web of Science ®Google Scholar
• Neel, B. G., Gu, H., & Pao, L. (2003). The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends in Biochemical Sciences, 28(6), 284–293. https://doi.org/10.1016/s0968-0004(03)00091-4
   PubMed Web of Science ®Google Scholar
• Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., Hsieh, T., Zaman, A., Olivas, V., McCoach, C., Blakely, C. M., Wang, Z., Kiss, G., Koltun, E. S., Gill, A. L., … Bivona, T. G. (2018). RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology, 20(9), 1064–1073. https://doi.org/10.1038/s41556-018-0169-1
   PubMed Web of Science ®Google Scholar
• Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018). Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nature Communications, 9(1), 4507. https://doi.org/10.1038/s41467-018-06814-w
   PubMedGoogle Scholar
• Pluskey, S., Wandless, T. J., Walsh, C. T., & Shoelson, S. E. (1995). Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains. The Journal of Biological Chemistry, 270(7), 2897–2900. https://doi.org/10.1074/jbc.270.7.2897
   PubMed Web of Science ®Google Scholar
• Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020). Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 26(7), 1633–1643. https://doi.org/10.1158/1078-0432.Ccr-19-3523
   PubMed Web of Science ®Google Scholar
• Song, Y., Wang, S., Zhao, M., Yang, X., & Yu, B. (2022a). Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy. Journal of Medicinal Chemistry, 65(4), 3066–3079. https://doi.org/10.1021/acs.jmedchem.1c02008
   PubMed Web of Science ®Google Scholar
• Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022b). Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials. Pharmacology & Therapeutics, 230, 107966. https://doi.org/10.1016/j.pharmthera.2021.107966
   PubMed Web of Science ®Google Scholar
• Sun, Y., Meyers, B. A., Czako, B., Leonard, P., Mseeh, F., Harris, A. L., Wu, Q., Johnson, S., Parker, C. A., Cross, J. B., Di Francesco, M. E., Bivona, B. J., Bristow, C. A., Burke, J. P., Carrillo, C. C., Carroll, C. L., Chang, Q., Feng, N., Gao, G., … Jones, P. (2020). Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward Osimertinib. Cancer Research, 80(21), 4840–4853. https://doi.org/10.1158/0008-5472.Can-20-1634
   PubMed Web of Science ®Google Scholar
• Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., Kalidas, K., Patton, M. A., Kucherlapati, R. S., & Gelb, B. D. (2001). Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nature Genetics, 29(4), 465–468. https://doi.org/10.1038/ng772
   PubMed Web of Science ®Google Scholar
• Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003). Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics, 34(2), 148–150. https://doi.org/10.1038/ng1156
   PubMed Web of Science ®Google Scholar
• Tiganis, T., & Bennett, A. M. (2007). Protein tyrosine phosphatase function: The substrate perspective. The Biochemical Journal, 402(1), 1–15. https://doi.org/10.1042/bj20061548
   PubMedGoogle Scholar
• Vazhappilly, C. G., Saleh, E., Ramadan, W., Menon, V., Al-Azawi, A. M., Tarazi, H., Abdu-Allah, H., El-Shorbagi, A.-N., & El-Awady, R. (2019). Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types. Investigational New Drugs, 37(2), 252–261. https://doi.org/10.1007/s10637-018-0626-5
   PubMed Web of Science ®Google Scholar
• Yang, J., Liu, L., He, D., Song, X., Liang, X., Zhao, Z. J., & Zhou, G. W. (2003). Crystal structure of human protein-tyrosine phosphatase SHP-1. The Journal of Biological Chemistry, 278(8), 6516–6520. https://doi.org/10.1074/jbc.M210430200
   PubMed Web of Science ®Google Scholar
• Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of Experimental Medicine, 209(6), 1201–1217. https://doi.org/10.1084/jem.20112741
   PubMed Web of Science ®Google Scholar
• Zhao, J.-F., Wang, R.-S., Lu, S.-Z., Guo, X.-J., Chen, Y., Li, L.-H., Ding, C.-H., & Liu, W.-S. (2022). Identification of the novel natural product inhibitors of SHP2 from the plant Toona sinensis: In vitro and in silico study. International Journal of Biological Macromolecules, 221, 679–690. https://doi.org/10.1016/j.ijbiomac.2022.09.042
   PubMed Web of Science ®Google Scholar